Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- The nicotine addiction cycle
- The biology of nicotine
- Gene and SNP summary
- Marginal tests
- Performance of the marginal test
- Pathway SNPs only
- Typical GWAS
- What are we missing?
- Testing G-E interactions (1)
- Power for the case-control analysis
- Case-control interaction test
- Testing G-E interactions (2)
- Case-only analysis
- Why the case-only approach works
- Case-only: much better power
- Case-control interaction test
- Case-only interaction test (1)
- Case-only interaction test (2)
- Interaction testing in case-control samples (1)
- Empirical Bayes weighted average
- A log-linear approach via BMA
- Weighted average of two models
- BMA type I error
- BMA empirical power
- EB/BMA Test
- Interaction testing in case-control samples (2)
- Joint tests of G and G-E interaction
- Joint test for main effect and interaction
- Joint test with case-only interaction
- BMA extension to GWAS
- BMA joint test
- BMA joint test across numerous SNPs
- Curse of multiple comparison correction
- Interaction testing in case-control samples (3)
- Interactions in a GWAS: 2-step approach
- Alternatives and extensions
- 2-step approach (D-G)
- Power for 2-step approaches
- Hybrid 2-step approach
- Joint 2-step approach (EDGxE)
- Power: EDGxE screen
- “Cocktail” 2-step spproach
- Simulation results (1)
- Simulation results (2)
- There is no clear winner!
- Agnostic gene-gene interaction scan
- 2-step gene-gene interaction
- Identified pathway in GWAS
- Interaction within a pathway
- Knowledge to guide search space
- PEAK
- Model space subsets
- Clustering of genes via GO terms
- Modify probability of inclusion
- Informative model search
- Acknowledgements
Topics Covered
- Biology of nicotine
- Marginal tests
- Case-control analysis
- Case-only analysis
- Empirical-Bayes weighted average
- Bayes model averaging
- Joint tests
- Screening approaches
- 2-step approaches
Talk Citation
Conti, D.V. (2016, November 30). GxE interactions in genome-wide association studies [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 23, 2024, from https://doi.org/10.69645/XQZA7854.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. David V. Conti has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Statistical Genetics
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is David Conti,
and I'm from the University
of Southern California.
And today, I am going to talk
about "GxE Environment
Interactions
in Genome-Wide
Association Studies".
0:10
Typically, in genetic
association studies,
we start with a phenotype.
And in this example,
we're starting
with cigarette smoking,
and the behavior of who smokes
and who doesn't.
From that step
of the phenotype,
we often try to key in
on the biology
and look at,
who's absorbing that nicotine
and how they absorb it
differently,
in terms of
nicotine metabolism.
That also then leads into
effects of the brain such arousal,
mood modulation, and pleasure.
Over time, as individuals
start ... continue to smoke,
there's a build-up of tolerance
and physical dependence.
This leads to drug abstinence
and withdrawal symptoms,
when one tries to quit smoking.
And then, of course,
the metabolism kicks in.
And there's a craving
for nicotine to self-medicate
that withdrawal symptoms
and to smoke again.
Based on this understanding
of the phenotype,
we often then
key in more on the resolution.
1:02
We focus on the biology
that's behind this.
And in this slide,
we can look at
in the upper right figure,
in the liver cell, we have
nicotine going to cotinine.
That's going to be a process
that is mediated
by certain genes,
CYP2A6, CYP2B6.
And then also the process of
how nicotine crosses
the blood brain barrier,
and how that gets
into the dopamine system
and the neuronic system.
And what genes are
involved in there.
Based again on that biology
in a genetic context,
we can move forward.
1:34
In which we sort of key in
on the key genes
that are involved
in that pathways,
and the SNPs
that might be involved.
And the SNPs being
the single-nucleotide
polymorphisms
within each gene.
Within each gene,
we can select these SNPs
that include
putative functional SNPs
as well as SNPs to capture
the overall genetic
architecture,
or the linkage disequilibrium,
or LD, between the SNPs.
We also can include SNPs
that are informative
for ancestry,
so we can control
for potential confounding
due to population
stratification.
So within this setting,
as we choose the set of SNPs,
we can then analyze this data
and see how
any of these individual SNPs
are associated
to the outcome of interest.